Phase 1b/2 Study Of Pf-04136309 In Combination With Gemcitabine And Nab-paclitaxel In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 29 Jun 2017
At a glance
- Drugs PF 4136309 (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CCR2i
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 22 May 2017 Status changed from recruiting to active, no longer recruiting.
- 18 May 2017 Planned End Date changed from 6 Jul 2019 to 2 Dec 2017.